In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 301 to 310 of 317

TitleTypeExpected publication date
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]Technology appraisal guidance
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidanceTBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidance
Vosoritide for treating achondroplasia in people 4 months and over ID6488Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All